EuroAPI Stock in 2026: Price, Spin-Off and Outlook

EuroAPI stock (ticker EAPI, Euronext Paris, ISIN FR0014008VX5) has become, in four years, the symbol of a French stock market disappointment: spun off from Sanofi in 2022 to strike out on its own, the maker of active pharmaceutical ingredients now trades at €0.79 — after falling 75.20% over one year and 83.43% over three years.

In 2026, the case for EuroAPI stock is an extreme turnaround bet. On one side: a share price below one euro, a consensus target of €1.00 still 25.63% above the market, and real industrial assets — plants, molecules, teams. On the other: two sell recommendations against zero buys, a target cut in half by a major bank, and Asian competition eroding the core of the business model. This profile examines both sides of the story without pulling punches.

Live EuroAPI Stock Price

EuroAPI is listed on Euronext Paris, in euros, Compartment B. As a French company, the stock is eligible for SRD (deferred settlement) and the PEA. This dual eligibility lets retail investors hold the stock in the most tax-efficient wrapper, though that has not stopped it from suffering one of the longest declines on the Paris market.

As of October 23, 2026, EuroAPI stock is trading at €0.79, up 1.15% on the session. Short time frames offer a semblance of respite: +6.13% over one week, +0.25% over one month. Medium time frames tell the real story: −35.07% over three months, −37.62% over six months, −75.20% over one year and −83.43% over three years.

Listed since 2022, the stock does not yet have a five- or ten-year track record — but over its available history, the trend is unequivocal: the stock has smashed through its historical support level of €2.10, a former technical floor that chartists saw as the last line of defense before uncharted price territory.

If you are building a portfolio of healthcare stocks, our profiles of Ensign Group stock and Erytech Pharma stock complement this analysis well.

EuroAPI Stock Profile

CompanyEuroAPI S.A.
TickerEAPI (Euronext Paris)
ISINFR0014008VX5
ExchangeEuronext Paris (in euros)
SectorPharmaceuticals — active pharmaceutical ingredients (APIs)
PEA / SRD eligibilityYes / Yes
Share price (October 23, 2026)€0.79
Consensus target€1.00 (+25.63%)
Estimated 2026 yieldNot meaningful (no dividend expected)

The Business: Making the Molecules in Medicines

EuroAPI produces active pharmaceutical ingredients — the molecules that treat patients, as opposed to the finished medicines sold in pharmacies. This fine pharmaceutical chemistry business, known in the industry as API, involves synthesizing molecules, sometimes highly complex ones, on an industrial scale for drugmakers that turn them into tablets, capsules or injectables.

The group’s historical positioning rests on two pillars. First, a long-established European industrial base — French and Italian production sites inherited from decades of pharmaceutical chemistry, with the regulatory approvals that come with them. Second, a catalog of so-called “critical” molecules, including active ingredients used in hospital treatments, where reliability of supply matters as much as price.

That is where the competitive problem lies: for high-volume molecules, Asian producers have much lower production costs, and pricing pressure is felt quarter after quarter. Newswires sum it up in one line: “Medicines: EuroAPI buckles under Asian competition.” It is this equation — quality assets versus European costs — that the new management has to solve.

Finally, it is worth mentioning the structure of the fine pharmaceutical chemistry market. A minority of molecules — hormones, antivirals, hospital anesthetics — require sophisticated production lines and constant regulatory oversight: this segment holds up, because switching suppliers means years of new approvals. Most active ingredients, however, are treated as commodities, bought at the best price, mainly in Asia. The group’s whole strategy is to shift its portfolio from the second category to the first — a slow, costly move that is never guaranteed.

History: The 2022 Spin-Off From Sanofi

EuroAPI was born in 2022 from a Sanofi spin-off: the French pharmaceutical giant carved out its active ingredient manufacturing operations into an independent company listed in Paris. The aim was to give these plants their own strategy — growing as a third-party supplier to drugmakers worldwide — away from the trade-offs of a group focused on medical innovation and vaccines.

Sanofi shareholders received EuroAPI shares in the distribution, and many of them discovered a little-known, industrial and capital-intensive business, far removed from pure pharmaceutical research. The stock’s early days attracted genuine interest, as the story of European health sovereignty offered an appealing narrative at a time of strain on global supply chains.

What followed did not live up to that story. Between executive departures, industrial restructuring and competitive pressure, the stock never found a lasting anchor: every attempted rebound was wiped out by a new series of bad news. The share price of €0.79 is the mechanical result — and the original reference shareholder has gradually reduced its stake, with the company no longer a heavyweight in pan-European indices.

The Fall: Reading Three Years of Value Destruction

PeriodPerformance
1 week+6.13%
1 month+0.25%
3 months−35.07%
6 months−37.62%
1 year−75.20%
3 years−83.43%

Reading this table calls for a kind of honesty that is rare in financial analysis: a stock that loses three quarters of its value in a year is not a “lagging opportunity”; it is first and foremost a sign of a deep deterioration in expectations. Two recent signals illustrate this better than any commentary.

The first comes from bank research: Deutsche Bank cut its price target on EuroAPI by 50% — a discouraging move that says everything about how valuation models have been recalibrated for the group’s future revenue. The second comes from the market itself: the break below the historical €2.10 level opened up uncharted technical territory, with no price reference for investors who might have wanted to buy “on support”.

Add to this a discreet but telling shareholder signal: the fund Kopernik Global Investors fell below the 5% threshold of the capital — a withdrawal that removes a structural buyer from the register at precisely the moment the stock most needs patient backers.

Rumors and the Group’s Response

In such a damaged situation, rumors once again become the daily driver of the share price — and EuroAPI was forced to “respond publicly to rumors” circulating about it, according to market newswires. Without prejudging the substance, the episode sheds light on the stock’s current psychology: at this price level, it moves to the rhythm of speculation — an industrial takeover, a capital restructuring, asset sales — more than to the rhythm of its industrial fundamentals.

For investors, this phase requires particular discipline. A rumor can deliver a 30% gain in a few sessions; it can also fizzle out and leave the share price falling back toward its underlying trend. Anyone wanting to treat EuroAPI as an event-driven bet must therefore set their position size in advance — small by design — and their exit rule, in both directions.

The group’s “results and outlook” publication remains the only event that really matters: that is where management can prove, with figures, that margin recovery and the shift toward critical molecules are materializing. Until proven otherwise, the market has stopped giving it the benefit of the doubt.

Analyst Consensus on EuroAPI Stock

As of October 18, 2026, the breakdown of recommendations is as unfavorable as it gets:

RecommendationNumber of analysts
Buy0
Outperform0
Hold1
Underperform1
Sell2

One important detail about this breakdown: even the most cautious analysts have not all cut their targets below the share price. The median target of €1.00, with its stated upside of +25.63%, does not reflect enthusiasm — it mainly measures how deep the fall has already been. When a stock loses 75% in a year, the remaining targets mechanically stay above the market; the recommendations, however, tell the truth of the moment: nobody is advising buying anymore.

Coverage itself has narrowed. Major international banks follow this now “special situation” from a distance, and the disappearance of buy recommendations removes one of the classic catalysts for a rebound — the gradual return of conviction buyers after sell calls, as seen in other European healthcare turnaround stories.

Tableau originalDiversifiez votre patrimoineInvestissez dans l’artDes tableaux originaux, pièces uniques signées par l’artiste. Un actif tangible, loin des écrans et des cotations.Voir les tableaux →

Dividend: No Payout in Sight

The estimated 2026 yield is nonexistent: no dividend is expected on the stock. In an industrial turnaround, this is not an anomaly but a logical consequence. The recovery the situation demands requires investing in the sites, funding the restructuring and preserving cash; paying cash out to shareholders would contradict the industrial rescue plan.

The implication for investors is clear: EuroAPI stock can only be justified in a portfolio by the expectation of a capital gain — not by a yield while you wait. Unlike the large French pharmaceutical stocks that reward patience, nothing here compensates for a thesis that drags on. It is a small conviction position, or nothing at all.

Risks to Know Before Buying

Competitive risk dominates: Asian pressure on prices for high-volume active ingredients will not disappear by decree. Execution risk follows close behind: the plan to reposition toward critical molecules and exclusive contracts will take years, and every missed quarter will send the stock back to its lows.

Funding risk cannot be ruled out: a small-cap company in restructuring may need to raise equity, diluting existing shareholders. Finally, liquidity risk: for a small stock shunned by institutional investors, bid-ask spreads widen and price moves are exaggerated in both directions — including on the downside on days of panic.

In terms of monitoring, two events are enough to frame the year: the annual accounts, which measure progress on the repositioning, and the general meeting, where changes in shareholding and governance can be seen. In between, news on the stock will remain dominated by rumors — an unstable trading regime suited to well-informed speculators and nobody else.

How to Buy EuroAPI Stock

If you are a beginner, start with our guide on how to invest in the stock market — all the more essential for a high-risk stock. Then follow these five steps:

  1. Open a securities account or a PEA with a regulated broker — our comparison of reputable, reliable trading sites compares fees, regulation and execution.
  2. Search for the stock using the ticker EAPI or the ISIN FR0014008VX5.
  3. Limit your position size: with a volatile stock at €0.79, the small-weighting rule — a few percent of your portfolio at most — applies more than anywhere else.
  4. Place a limit order: spreads are wide on this stock, and a market order can be costly.
  5. Follow the publications: half-year results, progress on the industrial repositioning, shareholder news and any capital transactions.

Taxation

In an ordinary securities account, capital gains and dividends are subject to the 30% flat tax (PFU), with the option of the progressive income tax scale. In a PEA, after five years of holding, gains are only subject to social charges of 17.2% — for this stock, the tax wrapper does nothing to offset the industrial risk, but it maximizes net performance if the turnaround ever materializes.

Should You Buy EuroAPI Stock in 2026?

The case for potential buyers: a share price below one euro that already prices in a very bleak scenario; real industrial assets with regulatory approvals that are hard to replicate; a residual median target of +25.63%; and the catalytic power of rumors on a small market cap.

The case for caution: zero buy recommendations and two sells; a bank target cut in half; structural Asian competition; no dividend at all; and the classic risk of neglected stocks — staying neglected for a long time while your portfolio stagnates.

The honest summary: EuroAPI stock has no place in a portfolio built for safety. It belongs in the speculative portion, with full awareness, for investors who accept the risk of losing their entire stake in exchange for a potentially high upside asymmetry. Within French healthcare, other stocks combine growth and visibility — such as long-followed biotechs like Valneva stock, which carry different but well-documented risks.

FAQ About EuroAPI Stock

What is EuroAPI’s share price today?

As of October 23, 2026, EuroAPI stock is trading at €0.79 on Euronext Paris, up 1.15% on the session. Over one year, the stock is down 75.20%, having broken below its historical €2.10 level.

Why has EuroAPI stock fallen so much?

The 83.43% drop over three years reflects pressure from Asian competition on high-volume active ingredients, the group’s successive restructurings and the deterioration in analyst expectations — illustrated by Deutsche Bank cutting its price target in half.

Is EuroAPI stock a good investment in 2026?

The October 18, 2026 consensus includes no buy recommendations: 1 hold, 1 underperform and 2 sells. The residual median target of €1.00 (+25.63%) reflects the scale of the fall more than a buy signal. The stock is a speculative turnaround play, not a core investment.

Does EuroAPI pay a dividend?

No. No dividend is expected for 2026: the group is devoting its resources to its industrial recovery. The investment thesis rests entirely on the expectation of a capital gain.

What is the link between EuroAPI and Sanofi?

EuroAPI was born in 2022 from a Sanofi spin-off, in which Sanofi carved out its active pharmaceutical ingredient manufacturing operations into an independent company listed in Paris. Sanofi shareholders at the time received EuroAPI shares in the distribution.

Is EuroAPI stock eligible for the PEA?

Yes. As a French company listed on Euronext Paris, EuroAPI is eligible for both the PEA and SRD. After five years of holding, gains are only subject to social charges of 17.2%.

What is the stock’s exact listing?

The stock trades under the code EPA: EAPI on Euronext Paris, ISIN FR0014008VX5 — the “Price” section of this profile details the full listing information and how to follow the live quote from France.

Conclusion: The Turnaround Bet in All Its Brutality

EuroAPI stock shows what a “turnaround stock” really means: a real company, real plants, a crushed share price — and so far no sign that the market believes the recovery story. The 75% drop over one year has already priced in a lot of bad news; by definition, it does not rule out further falls as long as proof is lacking.

For most savers, the answer is simple: move on and focus your capital on stocks with visible fundamentals. For the minority who understand what they are buying — pharmaceutical industrial assets at a fire-sale price, in exchange for a recovery scenario that has not yet happened — management discipline will make all the difference: a tiny position, a time horizon tied to upcoming publications, and no illusions about the role rumors play in the daily share price.

Prices and data as of October 23, 2026 (Euronext Paris, Boursorama). The estimates cited are analyst consensus estimates and may be revised. This article is for information purposes only and does not constitute investment advice: invested capital remains exposed to a risk of total loss.

Suivez-nous sur Telegram